Show simple item record

dc.contributor.authorYaqub, Sheraz
dc.contributor.authorBjørnbeth, Bjørn Atle
dc.contributor.authorAngelsen, Jon-Helge
dc.contributor.authorFristrup, Claus W.
dc.contributor.authorGrønbech, Jon Erik
dc.contributor.authorHemmingsson, Oskar
dc.contributor.authorIsaksson, Bengt
dc.contributor.authorJuel, Ingebjørg Soterud
dc.contributor.authorLarsen, Peter Nørgaard
dc.contributor.authorLindell, Gert
dc.contributor.authorMortensen, Frank V.
dc.contributor.authorMortensen, Kim Erlend
dc.contributor.authorRizell, Magnus
dc.contributor.authorSandström, Per
dc.contributor.authorSandvik, Oddvar Mathias
dc.contributor.authorSparrelid, Ernesto
dc.contributor.authorTaflin, Helena
dc.contributor.authorTaskén, Kjetil
dc.contributor.authorBrudvik, Kristoffer Watten
dc.contributor.authorFretland, Åsmund Avdem
dc.contributor.authorHorn, Arild
dc.contributor.authorKleive, Dyre
dc.contributor.authorLabori, Knut Jørgen
dc.contributor.authorLassen, Kristoffer
dc.contributor.authorRøsok, Bård Ingvald
dc.contributor.authorSøreide, Jon Arne
dc.contributor.authorTholfsen, Tore
dc.contributor.authorVillanger, Olaug
dc.contributor.authorWaage, Anne
dc.date.accessioned2022-01-31T09:07:44Z
dc.date.available2022-01-31T09:07:44Z
dc.date.created2022-01-12T14:09:32Z
dc.date.issued2021
dc.identifier.issn1745-6215
dc.identifier.urihttps://hdl.handle.net/11250/2975844
dc.description.abstractBackground Colorectal cancer is one the most common cancers in the western world with increasing incidence. Approximately 50% of the patients develop liver metastases. Resection of liver metastases is the treatment of choice although almost half of the resected patients get recurrence in the liver. Methods The ASAC trial is a Scandinavian, multicentre, double-blinded, randomized, placebo-controlled study to determine whether adjuvant treatment with low-dose aspirin (acetylsalicylic acid (ASA)) can improve disease-free survival in patients treated for colorectal cancer liver metastases (CRCLM). Up to 800 patients operated for CRCLM will be randomized to Arm#1 ASA 160 mg once daily or Arm#2 Placebo, for a period of 3 years or until disease recurrence. The patients will be recruited at all major hepatobiliary surgical units in Norway, Sweden and Denmark and have follow-up according to standard of care and the National Guidelines. Discussion The ASAC trial will be the first clinical interventional trial to assess the potential beneficial role of ASA in recurrence of CRCLM and survival. ASA is an inexpensive, well-tolerated and easily accessible drug that will be highly potential as adjuvant drug in secondary prevention of CRCLM if the study shows a beneficial effect. We will also determine the effect of ASA as adjuvant treatment on Health-Related Quality of Life and the cost-effectiveness.en_US
dc.language.isoengen_US
dc.publisherBMCen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleAspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trialen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright The Author(s). 2021en_US
dc.source.articlenumber642en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1186/s13063-021-05587-w
dc.identifier.cristin1979520
dc.source.journalTrialsen_US
dc.identifier.citationTrials. 2021, 22, 642.en_US
dc.source.volume22en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal